The Impact of Regulatory T Cells on Carcinogen-induced Sarcogenesis

Overview

Journal Br J Cancer

Specialty Oncology

Date 2007 Jun 15

PMID 17565340

Citations 33

Authors

G Betts

J Twohig

M van den Broek

S Sierro

A Godkin

A Gallimore

Affiliations

Soon will be listed here.

Abstract

Burnet proposed in the 1950's that the immune system is engaged in identifying and destroying abnormal cancerous cells. This process, termed immune surveillance, has been at the centre of intense debate for decades. Results using immunodeficient mice lend support to the immune surveillance hypothesis. We surmised that immune surveillance would be hampered by the inhibitory effect of naturally occurring FoxP3(+) regulatory T cells, a population of T cells shown to be present at an increased frequency in a variety of human tumours. The carcinogen, methylcholanthrene was injected subcutaneously into mice and the steady development of fibrosarcomas was observed over approximately 200 days. These fibrosarcomas were strikingly infiltrated with FoxP3(+) regulatory T cells implying that these cells impinge upon immune-mediated rejection of the tumour. This was confirmed by partial ablation of FoxP3(+) regulatory T-cell activity, which resulted in a marked reduction in tumour incidence. The reduction of tumour incidence was ablated in mice that lacked interferon gamma. These data offer strong support for the concept of immune surveillance and indicate that this process is limited by the inhibitory effect of FoxP3(+) regulatory T cells.

Citing Articles

Three-dimensional Imaging Reveals Immune-driven Tumor-associated High Endothelial Venules as a Key Correlate of Tumor Rejection Following Depletion of Regulatory T Cells.

Milutinovic S, Abe J, Jones E, Kelch I, Smart K, Lauder S Cancer Res Commun. 2023; 2(12):1641-1656.

PMID: 36704666 PMC: 7614106. DOI: 10.1158/2767-9764.CRC-21-0123.

Recent advances in the role of Th17/Treg cells in tumor immunity and tumor therapy.

Qianmei Y, Zehong S, Guang W, Hui L, Lian G Immunol Res. 2021; 69(5):398-414.

PMID: 34302619 DOI: 10.1007/s12026-021-09211-6.

Potential Prospect of CDK4/6 Inhibitors in Triple-Negative Breast Cancer.

Hu Y, Gao J, Wang M, Li M Cancer Manag Res. 2021; 13:5223-5237.

PMID: 34234565 PMC: 8257068. DOI: 10.2147/CMAR.S310649.

Thymic Function Associated With Cancer Development, Relapse, and Antitumor Immunity - A Mini-Review.

Wang W, Thomas R, Sizova O, Su D Front Immunol. 2020; 11:773.

PMID: 32425946 PMC: 7203483. DOI: 10.3389/fimmu.2020.00773.

Turning the Tide Against Regulatory T Cells.

Han S, Toker A, Liu Z, Ohashi P Front Oncol. 2019; 9:279.

PMID: 31058083 PMC: 6477083. DOI: 10.3389/fonc.2019.00279.

References

Baecher-Allan C, Brown J, Freeman G, Hafler D . CD4+CD25high regulatory cells in human peripheral blood. J Immunol. 2001; 167(3):1245-53. DOI: 10.4049/jimmunol.167.3.1245. View

Wolf D, Wolf A, Rumpold H, Fiegl H, Zeimet A, Muller-Holzner E . The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res. 2005; 11(23):8326-31. DOI: 10.1158/1078-0432.CCR-05-1244. View

Ghiringhelli F, Puig P, Roux S, Parcellier A, Schmitt E, Solary E . Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J Exp Med. 2005; 202(7):919-29. PMC: 2213166. DOI: 10.1084/jem.20050463. View

Prehn L, Kojima A . Paradoxical effect of three-day thymectomy on sarcogenesis in the mouse with different dosages of methylcholanthrene. Cancer Res. 1986; 46(10):4971-2. View

Nishikawa H, Kato T, Tawara I, Takemitsu T, Saito K, Wang L . Accelerated chemically induced tumor development mediated by CD4+CD25+ regulatory T cells in wild-type hosts. Proc Natl Acad Sci U S A. 2005; 102(26):9253-7. PMC: 1166632. DOI: 10.1073/pnas.0503852102. View

Curiel T, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P . Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004; 10(9):942-9. DOI: 10.1038/nm1093. View

Asano M, Toda M, Sakaguchi N, Sakaguchi S . Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation. J Exp Med. 1996; 184(2):387-96. PMC: 2192701. DOI: 10.1084/jem.184.2.387. View

Bennett C, Christie J, Ramsdell F, Brunkow M, Ferguson P, Whitesell L . The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet. 2001; 27(1):20-1. DOI: 10.1038/83713. View

Clarke S, Betts G, Plant A, Wright K, El-Shanawany T, Harrop R . CD4+CD25+FOXP3+ regulatory T cells suppress anti-tumor immune responses in patients with colorectal cancer. PLoS One. 2007; 1:e129. PMC: 1762416. DOI: 10.1371/journal.pone.0000129. View

10.

Erdman S, Poutahidis T, Tomczak M, Rogers A, Cormier K, Plank B . CD4+ CD25+ regulatory T lymphocytes inhibit microbially induced colon cancer in Rag2-deficient mice. Am J Pathol. 2003; 162(2):691-702. PMC: 1851156. DOI: 10.1016/S0002-9440(10)63863-1. View

11.

Wang Z, Hong J, Sun W, Xu G, Li N, Chen X . Role of IFN-gamma in induction of Foxp3 and conversion of CD4+ CD25- T cells to CD4+ Tregs. J Clin Invest. 2006; 116(9):2434-41. PMC: 1533873. DOI: 10.1172/JCI25826. View

12.

Sakaguchi S . Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol. 2005; 6(4):345-52. DOI: 10.1038/ni1178. View

13.

Lowenthal J, Corthesy P, Tougne C, Lees R, MacDonald H, Nabholz M . High and low affinity IL 2 receptors: analysis by IL 2 dissociation rate and reactivity with monoclonal anti-receptor antibody PC61. J Immunol. 1985; 135(6):3988-94. View

14.

Roncador G, Brown P, Maestre L, Hue S, Martinez-Torrecuadrada J, Ling K . Analysis of FOXP3 protein expression in human CD4+CD25+ regulatory T cells at the single-cell level. Eur J Immunol. 2005; 35(6):1681-91. DOI: 10.1002/eji.200526189. View

15.

Brunkow M, Jeffery E, Hjerrild K, Paeper B, Clark L, Yasayko S . Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet. 2001; 27(1):68-73. DOI: 10.1038/83784. View

16.

Kaplan D, Shankaran V, Dighe A, STOCKERT E, Aguet M, Old L . Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci U S A. 1998; 95(13):7556-61. PMC: 22681. DOI: 10.1073/pnas.95.13.7556. View

17.

Shimizu J, Yamazaki S, Sakaguchi S . Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol. 1999; 163(10):5211-8. View

18.

Burnet M . Cancer: a biological approach. III. Viruses associated with neoplastic conditions. IV. Practical applications. Br Med J. 1957; 1(5023):841-7. PMC: 1973618. DOI: 10.1136/bmj.1.5023.841. View

19.

Kelchtermans H, De Klerck B, Mitera T, Van Balen M, Bullens D, Billiau A . Defective CD4+CD25+ regulatory T cell functioning in collagen-induced arthritis: an important factor in pathogenesis, counter-regulated by endogenous IFN-gamma. Arthritis Res Ther. 2005; 7(2):R402-15. PMC: 1065335. DOI: 10.1186/ar1500. View

20.

Sutmuller R, van Duivenvoorde L, van Elsas A, Schumacher T, Wildenberg M, Allison J . Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med. 2001; 194(6):823-32. PMC: 2195955. DOI: 10.1084/jem.194.6.823. View